|
Drug therapy best reserved for aggressive stone disease
|
|
Pharmacotherapy for reducing risk of stone recurrence is best reserved for patients with more aggressive disease who are at higher risk for another stone-related event, reported Brett A. Johnson, MD, at the 2019 World Congress of Endourology in Abu Dhabi.
|
|
Get the data
|
